{"id":"NCT01241591","sponsor":"Pfizer","briefTitle":"A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis","officialTitle":"A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2013-01","completion":"2013-01","firstPosted":"2010-11-16","resultsPosted":"2014-05-07","lastUpdate":"2018-12-26"},"enrollment":1101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"CP 690,550 5 mg","otherNames":[]},{"type":"DRUG","name":"CP 690,550 10 mg","otherNames":[]},{"type":"BIOLOGICAL","name":"Etanercept 50 mg","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"CP 690,550 5 mg BID+Placebo BIW","type":"EXPERIMENTAL"},{"label":"CP 690,550 10 mg BID+Placebo BIW","type":"EXPERIMENTAL"},{"label":"Placebo BID+Etanercept 50 mg BIW","type":"ACTIVE_COMPARATOR"},{"label":"Placebo BID+Placebo BIW","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With a Physician's Global Assessment (PGA) Response of \"Clear\" or \"Almost Clear\" at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)","deltaMin":47.11,"sd":null},{"arm":"CP-690,550 10 mg BID + Placebo BIW","deltaMin":68.18,"sd":null},{"arm":"Placebo BID + Etanercept 50 mg BIW","deltaMin":66.27,"sd":null},{"arm":"Placebo BID + Placebo BIW","deltaMin":14.95,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG001 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":122,"countries":["Argentina","Austria","Belgium","Bosnia and Herzegovina","Bulgaria","Chile","Colombia","Croatia","Czechia","Denmark","France","Germany","Hong Kong","Hungary","Israel","Netherlands","Poland","Russia","Singapore","Slovakia","South Korea","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["32816215","27271195","26051365"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921080&StudyName=A%20Phase%203%2C%20Multi%20Site%2C%20Randomized%2C%20Double%20Blind%2C%20Placebo%20Controlled%20Study%20Of%20The%20Efficacy%20And%20Safety%20Comparing%20CP-%20690%2C550%20And"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":329},"commonTop":["Nasopharyngitis","Headache","Blood creatine phosphokinase increased","Hypercholesterolaemia","Dyslipidaemia"]}}